Chronic inflammatory diseases are complex to treat and have an impact on a large number of patients. Due to the difficulty of treating these diseases and the great impact on quality of life, patients often seek off-label, complimentary, or alternative medicines to gain relief from symptoms. Low-dose naltrexone has been used off-label for treatment of pain and inflammation in multiple sclerosis, Crohn's disease, fibromyalgia, and other diseases. Naltrexone is a mu-opioid receptor antagonist indicated by the U.S. Food and Drug Administration for opioid and alcohol dependence. It is hypothesized that lower than standard doses of naltrexone inhibit cellular proliferation of T and B cells and block Tolllike receptor 4, resulting in an analgesic and antiinflammatory effect. It is the purpose of this review to examine the evidence of the safety, tolerability, and efficacy of low-dose naltrexone for use in chronic pain and inflammatory conditions. Currently, evidence supports the safety and tolerability of low-dose naltrexone in multiple sclerosis, fibromyalgia, and Crohn's disease. Fewer studies support the efficacy of low-dose naltrexone, with most of these focusing on subjective measures such as quality of life or self-reported pain. These studies do demonstrate that low-dose naltrexone has subjective benefits over placebo, but evidence for more objective measures is limited. However, further randomized controlled trials are needed to determine the efficacy of low-dose naltrexone due to insufficient evidence supporting its use in these disease states. This review provides practitioners with the extent of low-dose naltrexone evidence so that they can be cognizant of situations where it may not be the most appropriate therapy.
Approximately 259 million prescriptions for opioids were written in 2012 for use in both acute and chronic pain. 1 Since the 1990s, opioid prescriptions have been increasing in prevalence in chronic inflammatory conditions and chronic neuropathic conditions 2 despite most opioids being considered less effective or having unproven efficacy in these chronic conditions. 3 Conditions such as these have a large impact on quality of life and affect a great number of patients. For example, in the United States, multiple sclerosis (MS) is estimated to affect over 42 million patients, 4 as many as 1.3 million people suffer from inflammatory bowel disease, 5 and fibromyalgia affects about 4 million people. a result, many of these patients seek out complementary or alternative medicines. This is generally done in hopes of gaining greater relief from pain and other symptoms and to boost the immune system. 7 Low-dose naltrexone (LDN) has become increasingly more common for off-label use in chronic diseases and pruritus. 8 While the exact prevalence of LDN prescriptions in the United States is challenging to determine, in Norway, 0.3% of the population has been shown to have used LDN. 9 However, use may not be unusual in the United States as evidenced by more than 250 pharmacies that compound it nationwide. 10 Information on LDN is widespread on the Internet and in the popular press, although these sources rarely make use of peer-reviewed evidence.
While public opinion of LDN appears to be high and widely spread by word of mouth, 11 this has led to the dissemination of misinformation. As such, drug safety, patient welfare, and efficacy of LDN need to be carefully considered and examined in detail in order to inform health care professionals about the quality of the evidence for use in their practice. As a result, this review includes articles on LDN using the following key words and MeSH terms: naltrexone, naltrexone/administration & dosage, naltrexone/adverse effects, naltrexone/therapeutic use, low dose naltrexone, LDN, low-dose, and narcotic antagonists.
Mechanisms of Action

Pharmacokinetics
Naltrexone is almost completely absorbed orally, widely affected by the first-pass effect, broadly distributed throughout the body, and extensively metabolized by a non-cytochrome dehydrogenase enzyme to its active metabolite, 6-beta-naltrexol. The half-life elimination of naltrexone can vary depending on route of administration, with oral being 4 hours for naltrexone and 13 hours for 6-beta-naltrexol and intramuscular being 5-10 days for naltrexone and its metabolite combined. The reason for the difference between these routes of administration is the use of a slowly eroding polymer in the intramuscular formulation. Naltrexone and its metabolite are excreted primarily in the urine, but no dosing adjustments are needed in mild renal impairment. The necessity of dosing adjustments in moderate to severe renal impairment was not studied by the manufacturer. 12 Opioid Antagonism Naltrexone is currently indicated by the U.S. Food and Drug Administration (FDA) only for treatment of opioid and alcohol dependence. When combined with an opioid agonist, naltrexone works as an abuse deterrent complementing the use of opioids in management of chronic pain. These effects occur through competitive opioid receptor antagonism, especially through blockade of mu-opioid receptors. 12 In addition to antagonism of opioid receptors, chronic naltrexone use has been demonstrated in rats to increase sensitivity to opioids as well as to increase opioid receptor density. 13 This can enhance analgesia, both opioid and endogenous, in addition to deterring abuse, leading to the formulations where naltrexone is combined with an opioid. 
Toll-Like Receptor 4 Blockade
The mechanisms for LDN may differ from the mechanism of action that occurs in standard dosing regimens. One rat study demonstrated that only a small dose of naloxone is needed to impact some of the functions of glial cells and macrophages.
14 A different in vitro study suggests that this may also be the case with naltrexone, although more weakly than naloxone. 15 Astrocytes and microglia can initiate a proinflammatory cytokine cascade in response to pain 16 and can contribute to neuropathic pain enhancement and opioid-tolerance. 17 Much of this is done through the binding of Toll-like receptors found on glia cells throughout the central and peripheral nervous systems. 18 Opioid medications have been shown in rats to induce Toll-like receptor 4 (TLR4) signaling, which can lead to opioid-induced proinflammatory effects. 19 However, it has been shown in both rat and in vitro studies that naltrexone can inhibit this proinflammatory pathway by inhibiting TLR4 signaling. 15, 20, 21 Because TLR4 is more prevalent on microglia than it is on astrocytes, LDN could have use as a potential immunomodulator through the suppression of the innate immune cells of the nervous system. 20, 21 Because microglial activation is associated with neuropathic pain, 17 the inhibition of microglial activation could lead to a reversal of neuropathy as well. 15 By blocking TLR4, naltrexone inhibits production of the proinflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha as well as inflammatory factor nitric oxide (NO), 20, 21 which contributes to pain sensitization via processing of nociceptive signals. 22 The reduction in IL-6 and TNF-alpha has been shown in vitro and in vivo to cascade into a reduction of a variety of other cytokines. 20, 23 Interestingly, naltrexone inhibits TLR4 without inhibiting cytokine secretion after TLR4 has been stimulated with lipopolysaccharide, meaning that naltrexone does not inhibit the receptor response to the presence of gram-negative bacteria. 20 Opioid Growth Factor-Opioid Growth Factor Receptor Axis Regulation
In the late 1980s, a nonclassic opioid receptor was discovered that resided on the nuclear membrane. 24 While originally termed the zeta-opioid receptor, it was later renamed as the opioid growth factor (OGF) receptor (OGFr) to distinguish it from the neurotransmitter function that other opioid receptors possess. Opioid growth factor receptor has been linked with inhibition of cellular proliferation, 25 specifically through inhibition of DNA synthesis as demonstrated in mice. 26 Use of LDN has been proposed to alter the OGF-OGFr axis in a variety of disease states. Using mouse models, several researchers have hypothesized that these diseases have a dysregulation of the OGF-OGFr axis where either too little OGF, also called [met5]enkephalin, is naturally produced or the OGF that is naturally produced is unable to bind to the OGFr effectively due to altered receptor sensitivity. [27] [28] [29] The binding of LDN to OGFr competitively inhibits the binding of OGF. However, with LDN this binding occurs only for a short duration. 29 The oral half-life of naltrexone is 4 hours, 12 and the typical dosing of LDN is 1-4.5 mg daily, which is the dosing used in the studies described later. [30] [31] [32] With high doses, the amount of naltrexone present is metabolized over a longer period, so the blockade of OGFr is continuous, resulting in enhanced cellular proliferation. 29, 33 In contrast, the low-dose formulation achieves an intermittent blockade due to the small dose being metabolized long before the next daily dose is administered. [30] [31] [32] The intermittent blockade results in reduced cellular proliferation of T and B cells. 27 The short duration of the blockade initiates a compensatory mechanism, upregulating the production of OGF, increasing cellular production of OGFr, and increasing the sensitivity of OGFr. 29 Once the naltrexone is metabolized and the receptors are no longer blockaded, a period of heightened interaction occurs between OGF and OGFr, and this rebound effect is hypothesized to return the OGF-OGFr axis to homeostasis. 26, 28, 29 Safety, Tolerability, and Efficacy These proposed mechanisms of action suggest that LDN may operate as a novel nervous system antiinflammatory and immunomodulator. Additionally, through the modulation of pain sensitivity, LDN may also serve as an analgesic in addition to these antiinflammatory effects. The result of these mechanisms is that LDN is proposed to reduce the severity of symptoms in a wide range of chronic inflammatory and centralized pain sensitization conditions. It has also been proposed that due to the inhibited cellular proliferation associated with intermittent OGFr blockade that LDN may have value in an oncological setting as well.
Multiple Sclerosis
Because of need for immunomodulation, several studies have begun to look at safety and tolerability of LDN in MS. One such study, a retrospective chart review, looked at 215 participants who were prescribed LDN for MS. 34 This study reported that 77% of the participants reported no side effects from the use of LDN and no participants were hospitalized from adverse effects due to LDN. No side effects were reported from drug interactions with the disease-modifying therapies of the participants, although no participants received chronic opioids alongside LDN. Most of the participants were initiated on LDN due to fatigue, and almost 60% reported a reduction in fatigue. Most of the other participants reported no change in energy levels, and only four participants stated that LDN increased their fatigue levels. Additionally, 75% of the participants reported perceiving an increased or stabilized quality of life after LDN therapy.
Other retrospective chart reviews have attempted to also address the effectiveness of LDN alongside safety and tolerability. One such study looked at relapsing-remitting MS patients who were prescribed either LDN alone (23 participants) or as an adjunctive therapy to treatment with glatiramer acetate (31 participants). 35 Both the LDN alone and the LDN combined with glatiramer groups had comparable number of MS flares during the duration of the study. Magnetic resonance images taken of the two cohorts showed a lack of disease progression in either; walking function tests performed by both groups were comparable; and blood values and behavioral data showed no significant adverse effects in the two groups. Overall, the outcomes from both groups were equivalent. However, the small number of participants makes it more challenging to generalize the findings to a diverse population.
In recent years, several studies have examined the efficacy of LDN in MS, as safety and tolerability are well established. However, any evidence of LDN modifying MS disease progression has been limited to animal studies. One study used a MS analog mouse model with experimental autoimmune encephalomyelitis (EAE) that had been exposed to either OGF, LDN, or saline daily for 60 days. 36 The mice showed no exacerbations of EAE or disease symptoms during the period they were treated with OGF or LDN and showed no detrimental effects to the treatment. In addition, the mice in the OGF and LDN groups also showed reduction in activated astrocytes, decreased disease scores, and decreased behavioral signs and had less demyelination as compared to controls.
While these results are promising, there are fundamental limitations in what can be extrapolated from an animal model. This has prompted a search for a biomarker that could be used to track clinical efficacy in humans, as outcomes such as decreased demyelination are not easily measured in humans. One such study proposed changes in serum OGF levels, as these are reduced in both MS and EAE compared to healthy controls. 37 These levels are also restored with LDN therapy, supporting the concept that LDN may modulate the OGF-OGFr axis in MS.
In humans, LDN has not demonstrated any disease-modification effects in MS. However, efficacy outcomes regarding improved quality of life and pain reduction have occurred in two recent studies. One of these studies, a doubleblind crossover study, looked at 60 participants and reviewed their mental and physical health, pain, and any perceived deficits in functioning. 31 This placebo-controlled study found improvements in mental health outcomes and symptomatic pain, even though it showed no significant changes in physical outcomes, such as bladder and bowel control, visual impairment, or sexual satisfaction. Whereas it is possible that LDN may have improved the physical health of these participants, this could not be assessed in the limited 8-week duration of this study.
The other of the two studies was 17 weeks and looked at a multidimensional, quality-of-life questionnaire. 38 This study found improvements in the perception the participants had regarding their own health, but no improvements were reported in pain, energy levels, or physical functioning. These increases in the perception of health improvement and reported changes in mental health may be associated with the effect of LDN on OGF levels. 37, 39 One pilot trial did show clinical efficacy for one aspect of physical functioning. 39 This study showed a significant reduction in spasticity, measured using the Modified Ashworth Scale, that persisted for up to a month after the discontinuation of LDN. However, this trial was open label and uncontrolled, and spasticity was analyzed only as a secondary outcome based on intention-to-treat. Regardless, this decrease in spasticity paralleled the observed increased betaendorphin levels in the participants.
In summary, although LDN has repeatedly demonstrated safety and tolerability, studies examining efficacy in treating MS have been limited. Currently, there is little evidence to suggest LDN as a possible therapeutic for this disease.
Fibromyalgia
While fibromyalgia is not considered a classic inflammatory disease, it is considered to be a disorder of the central nervous system that has a neuroimmune component. 40 The effect LDN has as an immunomodulator may be beneficial for use in fibromyalgia, and pilot studies have begun to evaluate how LDN treatment could impact fibromyalgia patients. One crossover study looked at the serum cytokine levels of eight women over the course of 10 weeks. 23 This single-blind trial also looked at fibromyalgia-associated pain and symptoms as compared to baseline for each participant. After 8 weeks of therapy with LDN, a variety of proinflammatory markers were reduced, especially those associated with nociception and allodynia. The participants reported significantly less pain and symptoms associated with their fibromyalgia, and no moderate or major adverse effects were reported.
Another recent open-label study also looked at the safety and effectiveness of LDN in fibromyalgia patients with a focus on physical functioning, pain, mental health, and adverse effects using a validated self-report questionnaire. 41 At the end of the 90-day period, half of the participants experienced a 40% improvement in symptoms and functioning, and there was a 19.5% overall improvement across all participants. However, the effectiveness of LDN is unresolved by this study as a substantial portion of fibromyalgia patients have concomitant autoimmune disorders, and such participants were excluded.
Overall, studies on the clinical efficacy of LDN in fibromyalgia, like in MS, are focused on pain improvement and quality of life. A recent pilot study found a significant improvement in daily pain, stress, and fatigue associated with fibromyalgia. 42 Severity of symptoms was tracked through a daily reporting via a 0-100 visual analog scale, and the patients also underwent mechanical, thermal, and cold pain assessments every 2 weeks. Overall, the participants experienced a significant reduction in fibromyalgia symptoms. However, the study only included 12 participants, who all followed the same treatment schedule. Additionally, a notable effect of LDN in fibromyalgia has been on increasing pain tolerance. One case report involved a patient with fibromyalgia on a daily LDN dose of 6 mg undergoing a cold pressor test (CPT) to determine pain tolerance every few weeks along with self-reporting the patient's quality of life and general pain. After 18 weeks of LDN therapy, the patient's CPT time increased 10-fold. 43 An additional small double-blinded crossover study of 31 participants showed a significant reduction in daily pain as compared to placebo and baseline pain. 32 The participants reported not only reduction in daily pain but also significantly increased quality of life and mood.
Similar to its role in MS, LDN has demonstrated safety and tolerability in fibromyalgia patients. In preliminary studies, however, the efficacy of LDN in fibromyalgia has not yet been sufficiently demonstrated. Larger studies, with better control over variables and participants, are needed to support the use of LDN in patients with fibromyalgia.
Crohn's Disease
As a more classic inflammatory disease, Crohn's has been looked at as a potential target of LDN therapy for about a decade. Two reviews, one by the Cochrane Library, concluded that although there is some evidence regarding the safety and efficacy of LDN for use in Crohn's disease, the data are from a small number of studies and participants. 11, 44 However, these reviews do agree that there does not appear to be an increase in the rates of adverse effects in LDN as compared to placebo, and so preliminary evidence is that LDN is well tolerated by patients.
Only one study has addressed clinical efficacy in Crohn's disease. 30 Although the results of this study showed an 88% decrease in severity of symptoms in the LDN group and only a 40% decrease in the placebo group, the subject size was quite small, including only 40 patients with Crohn's. None of the participants in the placebo group improved in disease severity as determined by endoscopic examination compared to baseline, whereas 48% of the LDN group improved from baseline. This study was then bridged into an extended open-label study for the participants who had been randomized to placebo, and these participants then experienced a significant improvement in both self-reported severity of symptoms and severity of disease as determined by endoscopy. Although the decrease in symptoms and inflammation is promising, there was no significant improvement in qualityof-life measures.
The studies used to determine the safety and efficacy of LDN in Crohn's disease did not include many patients, and outcome measures were largely subjective. As is the case with LDN in most patient groups, it appears to be safe and well tolerated. While there may be a benefit to clinical response, there is a limited number of and scope of studies to provide evidence for efficacy of LDN in Crohn's disease. Currently, it must be concluded that efficacy of LDN in Crohn's disease as well cannot be established.
Cancer
The use of LDN as a potential anticancer agent has been researched for some time. The mechanism is presumed to be due to inhibition of cellular proliferation that occurs with intermittent blockade of OGFr. However, evidence from large-scale trials does not yet exist. A few case studies and pilot trials have shown that LDN is tolerated and may be effective in several cancers, [45] [46] [47] [48] but efficacy studies showing a change to disease progression in cancer have only been shown in animal models. 26, 33, 49 These case studies also had a greater variation in dosing of LDN, ranging from 0.5 to 5 mg once daily.
To date, no studies in human participants have shown any clinical efficacy of LDN in any type of cancer for either disease modification or quality-of-life outcomes. In fact, one pilot trial of 110 participants randomized to either LDN or placebo did hypothesize that LDN would have an impact on the quality of life and fatigue of high-grade glioma patients, as well as changes in functional capacity and neurocognitive function as secondary outcomes. 47 The percent decrease from baseline was not significant for quality of life, fatigue, or either of the secondary outcomes. However, this study was limited by a high dropout rate among participants in both groups and reported technical problems with the data measured to an extent that the researchers thought that the results were uninterpretable.
Due to only a small number of participants and high rates of complications in cancer, the tolerability of LDN has not yet been demonstrated in this disease state. With no human participant study showing clinical efficacy, there is currently little evidence to suggest that LDN should be used as a therapy in any type of cancer.
Other Chronic Pain Disorders
Due to the possibility of its use as a novel analgesic and antiinflammatory, there are a handful of recent case reports of the use of LDN in other chronic pain disorders. These include one in diabetic neuropathy, 50 one in chronic back pain, 51 and two in complex regional pain syndrome (CRPS), which is a loosely defined chronic pain and inflammation syndrome believed to be caused by a malfunctioning of the nervous system. 52, 53 In all four case reports, the patients reported no adverse effects, and all experienced a significant improvement in daily pain. One of the CRPS participants also experienced a decrease in fatigue in addition to a remission of CRPS.
Currently, trials concerning the efficacy of LDN in other chronic diseases are sparse. Only one study has addressed the subject of the clinical efficacy of LDN and in only one disease: Charcot-Marie-Tooth (CMT), an inherited peripheral neuropathic disorder resulting in axonal degeneration. This study was robustly designed and looked at efficacy of a combination drug called PTX3003 (which was LDN in one of three dose combinations with baclofen and sorbitol) as compared to placebo. 54 This combination of medications is thought to induce Schwann cell regeneration in this disease state through pleiotropic effects. 55 Participants receiving LDN showed a significant improvement in clinical outcomes, including sensory symptoms, motor symptoms, and limb strength. Additionally, participants who did not deteriorate in functionality over the course of the study were significantly more frequently in the highest dose of PXT3003. This study also compared PXT3003 to two studies of the effect of ascorbic acid in CMT participants, 56, 57 and PXT3003 showed superiority. However, due to the very slow progression of CMT, 1 year may not have been a long enough period to fully elucidate the efficacy of this treatment, and because only combination therapies were studied, to what extent these results are contributable to LDN specifically is unknown. Additionally, CMT is a rare genetic disease with no approved treatments to use as reference, and so the authors do not consider this trial to be conclusive of the efficacy of LDN.
The evidence for use of LDN in a variety of chronic pain conditions preliminarily supports the safety and tolerability. Except for in CMT, no efficacy studies have been performed, and as such, there is no evidence supporting the use of LDN in these disease states.
Logistical Challenges of Study Design
Despite the fact that LDN has been demonstrated to be safe and well tolerated, the evidence showing any efficacy regarding analgesic, antiinflammatory, and disease progression effects is still preliminary. Future clinical research will need to be robust, double-blinded, randomized controlled trials that contain an appropriate number of participants in order to gain FDA approval for a new indication. Such studies should also consider tracking potential biomarkers such as serum cytokines, beta-endorphin, or serum OGF levels in addition to pain, quality of life, and disease progression measures.
Naltrexone, no longer under patent, is inexpensive, and so there is limited financial incentive for large-scale trials to be conducted. LDN would need FDA approval for a new indication in order for exclusivity to be granted 58 and for LDN to be a viable investment for large-scale research. Considering the variety of disease states for which LDN may be a candidate, this still remains a possibility. Additionally, because LDN currently needs to be compounded, a manufactured reformulation could also be approved as a way to grant exclusivity. 58 Due to the lipophilicity of naltrexone, a reformulation is not limited to only oral products as naltrexone can also be formulated into transdermal products 59 or into combination-drug products, 54 allowing for other possibilities by which a patent could be pursued. Because LDN is currently compounded at numerous pharmacies across the country, these pharmacies have unique access to a large number of patients taking the medication. These pharmacists could potentially contribute significantly to the literature if they were able to design a study examining the efficacy of LDN using these data.
Conclusion
While some animal and in vitro studies support the use of LDN, its clinical efficacy as an analgesic and antiinflammatory has been tested only in a small number of chronic conditions such as MS, fibromyalgia, Crohn's disease, and CMT. Additionally, the efficacy of LDN for disease modification in various chronic conditions is not well established. As a result, the overall quality of the evidence thus far is insufficient to allow any definitive conclusions as to the efficacy of LDN for analgesia, antiinflammation, or disease modification. This means it currently may be premature to recommend LDN as an effective medication due to a lack of high-quality evidence.
Despite this limited evidence, LDN prescriptions are still compounded extensively for a variety of off-label indications such as chronic pain, inflammation, and pruritus. The large off-label use of LDN may be driven by patients looking to relieve symptoms, for alternatives to chronic opioid use in those diseases where opioids are indicated, or to improve quality of life. 7 Patients with refractory diseases may look for treatments that are safe and are outside the usually prescribed therapies. While LDN has the potential to be a useful medication, health care providers should be aware of how limited the evidence of efficacy is at present. This allows providers to assist their patients in filtering out misinformation. While LDN has a history of being safe and well tolerated, if it is not efficacious, then it would be affecting patients financially without any benefit. As 86% of health care spending is in patients with chronic conditions, this is especially problematic for patients who may already have a high financial burden due to the cost of their illness. 60 Perhaps with future clinical research, LDN may be shown to be not just safe but also effective for use as an immunomodulator, non-opioid analgesic, or novel antiinflammatory in a variety of chronic disease states that are currently challenging to treat.
